{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:03:23Z","timestamp":1787313803100,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["947081"],"award-info":[{"award-number":["947081"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pupt.2025.102364","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T02:48:50Z","timestamp":1748918930000},"page":"102364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-1936","authenticated-orcid":false,"given":"Jennifer Ann","family":"Kricker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael John","family":"Parnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2025.102364_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107839","article-title":"Therapeutic targets in lung tissue remodelling and fibrosis","volume":"225","author":"Liu","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"Suppl 9A","key":"10.1016\/j.pupt.2025.102364_bib2","first-page":"12S","article-title":"Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases","volume":"117","author":"Kudoh","year":"2004","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.pupt.2025.102364_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pharmrev.121.000300","article-title":"Nonantimicrobial actions of macrolides: overview and perspectives for future development","volume":"73","author":"Kricker","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.pupt.2025.102364_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pupt.2025.102364_bib5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1159\/000517781","article-title":"Efficacy of low-dose versus high-dose continuous cyclic azithromycin therapy for preventing acute exacerbations of COPD","volume":"100","author":"Pomares","year":"2021","journal-title":"Respiration (Basel)"},{"key":"10.1016\/j.pupt.2025.102364_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2147\/COPD.S284397","article-title":"Long-term azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease","volume":"16","author":"Talman","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"12","key":"10.1016\/j.pupt.2025.102364_bib7","doi-asserted-by":"crossref","first-page":"1362 e1361","DOI":"10.1016\/j.amjmed.2015.07.032","article-title":"Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly","volume":"128","author":"Taylor","year":"2015","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.pupt.2025.102364_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.coph.2008.01.010","article-title":"Macrolides as immunomodulatory medications for the therapy of chronic lung diseases","volume":"8","author":"Lopez-Boado","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pupt.2025.102364_bib9","series-title":"Macrolides as Immunomodulatory Agents","first-page":"3","article-title":"Macrolides and diseases associated with loss of epithelial barrier integrity","author":"Page","year":"2024"},{"issue":"5","key":"10.1016\/j.pupt.2025.102364_bib10","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/AAC.50.5.1805-1812.2006","article-title":"Novel effects of azithromycin on tight junction proteins in human airway epithelia","volume":"50","author":"Asgrimsson","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.pupt.2025.102364_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-019-1101-3","article-title":"Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia","volume":"20","author":"Arason","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2025.102364_bib13","series-title":"Paper Presented at the European Respiratory Congress (ERS) 2024","article-title":"The new macrolide EP395 reduces airway eosinophilic inflammation","author":"Kricker","year":"2024"},{"issue":"Pt 6","key":"10.1016\/j.pupt.2025.102364_bib14","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1042\/BST0351492","article-title":"Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease","volume":"35","author":"Sabroe","year":"2007","journal-title":"Biochem. Soc. Trans."},{"issue":"4","key":"10.1016\/j.pupt.2025.102364_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00281-016-0561-5","article-title":"COPD immunopathology","volume":"38","author":"Caramori","year":"2016","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.pupt.2025.102364_bib16","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/AAC.49.6.2372-2377.2005","article-title":"Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin","volume":"49","author":"Bosnar","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.pupt.2025.102364_bib17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaip.2018.01.025","article-title":"Inhaled corticosteroids safety and adverse effects in patients with asthma","volume":"6","author":"Heffler","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2025.102364_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2016_71","article-title":"Xanthines and phosphodiesterase inhibitors","volume":"237","author":"Spina","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pupt.2025.102364_bib39","article-title":"Barriolides: Non-antibacterial compounds with epithelial barrier enhancing properties and anti-inflammatory effects in vitro","author":"Kricker","year":"2022","journal-title":"Pharm Advances, 4, special issue"},{"issue":"6","key":"10.1016\/j.pupt.2025.102364_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","article-title":"Immunomodulation by macrolides: therapeutic potential for critical care","volume":"8","author":"Reijnders","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2025.102364_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41423-022-00946-2","article-title":"Surfactant protein D inhibits lipid-laden foamy macrophages and lung inflammation in chronic obstructive pulmonary disease","volume":"20","author":"Hsieh","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.pupt.2025.102364_bib21","series-title":"Paper Presented at the 2023 ERS International Congress, Milan, Italy","article-title":"EP395 effect on cell diapedesis measured by intravital microscopy","author":"Riffo-Vasquez","year":"2023"},{"issue":"3","key":"10.1016\/j.pupt.2025.102364_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culic","year":"2002","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2025.102364_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.pupt.2025.102364_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/0091-6749(88)90964-5","article-title":"Release of lysosomal enzyme beta-glucuronidase from isolated human eosinophils","volume":"82","author":"Marshall","year":"1988","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2025.102364_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pharmthera.2007.11.001","article-title":"Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action","volume":"117","author":"Shinkai","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2025.102364_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.pupt.2025.102364_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-00477-9","article-title":"Regulation of immune responses by the airway epithelial cell landscape","volume":"21","author":"Hewitt","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2025.102364_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12931-018-0752-9","article-title":"Oxidative stress enhances the expression of IL-33 in human airway epithelial cells","volume":"19","author":"Aizawa","year":"2018","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.pupt.2025.102364_bib29","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41598-018-21589-2","article-title":"Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage","volume":"8","author":"Scott","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.pupt.2025.102364_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2022","article-title":"Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE\/EGFR signalling complex","volume":"62","author":"Strickson","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.pupt.2025.102364_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41577-021-00538-7","article-title":"Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?","volume":"21","author":"Akdis","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.pupt.2025.102364_bib32","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/jpc.16197","article-title":"Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions","volume":"58","author":"Binns","year":"2022","journal-title":"J. Paediatr. Child Health"},{"issue":"10","key":"10.1016\/j.pupt.2025.102364_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory syncytial virus (RSV): a scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.pupt.2025.102364_bib34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2025.102364_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112682","article-title":"Antiviral effects of azithromycin: a narrative review","volume":"147","author":"Khoshnood","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.pupt.2025.102364_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2163","article-title":"Azithromycin in viral infections","volume":"31","author":"Oliver","year":"2021","journal-title":"Rev. Med. Virol."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553925000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553925000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:40:49Z","timestamp":1762364449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553925000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"alternative-id":["S1094553925000215"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102364","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102364"}}